Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 4/2019

06.05.2019 | Original Article

ICORG 06-35: a prospective evaluation of PET-CT scan in patients with non-operable or non-resectable non-small cell lung cancer treated by radical 3-dimensional conformal radiation therapy: a phase II study

verfasst von: Karla A. Lee, Guhan Rangaswamy, Naomi A. Lavan, Mary Dunne, Conor D. Collins, Cormac Small, Pierre Thirion

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiotherapy (RT) is a key treatment modality in the curative treatment of patients with non-small cell lung cancer (NSCLC). Incorrect definition of the gross, or clinical, target volume is a common source of error which can lead to a reduced probability of tumour control.

Objective

This was a pilot and a phase II study. The pilot evaluated the technical feasibility of integrating positron emission tomography–computed tomography (PET-CT) fusion. The primary outcome of the phase II study was to evaluate the safety of PET-CT scan–based RT by evaluating the rate of loco-regional recurrence outside the PET-CT planning target volume (PTV) but within conventional 3-D PTV.

Methods

Patients underwent standard post-treatment follow-up, including repeated three monthly CT scans of the thorax. In case of loco-regional recurrence, three categories were considered, with only extra-PET scan PTV and intra-CT scan PTV recurrences considered as a failure. Our hypothesis was that the rate of these events would be < 10%.

Results

Twelve patients were recruited; the study closed early due to poor recruitment. The primary endpoint of the pilot was met; it was feasible to deliver a PET-CT-based plan to ≥ 60% of patients. Two patients had intra-PET scan PTV recurrences, six had extra-PET scan PTV and extra-CT, and three patients had both. Another patient had extra-PET scan PTV and extra-CT as well as extra-PET scan PTV and intra-CT scan PTV recurrence.

Conclusion/advances in knowledge

PET-based planning has the potential to reduce radiation treatment volumes because of the avoidance of mediastinal lymph nodes that are PET negative.
Literatur
1.
Zurück zum Zitat Levi F, Lucchini F, La Vecchia C, Negri E (1999) Trends in mortality from cancer in the European Union, 1955-94. Lancet (London, England). 354(9180):742–743CrossRef Levi F, Lucchini F, La Vecchia C, Negri E (1999) Trends in mortality from cancer in the European Union, 1955-94. Lancet (London, England). 354(9180):742–743CrossRef
3.
Zurück zum Zitat Dogan N, Leybovich LB, Sethi A, Emami B (2002) Improvement of dose distributions in abutment regions of intensity modulated radiation therapy and electron fields. Med Phys 29(1):38–44PubMedCrossRef Dogan N, Leybovich LB, Sethi A, Emami B (2002) Improvement of dose distributions in abutment regions of intensity modulated radiation therapy and electron fields. Med Phys 29(1):38–44PubMedCrossRef
4.
Zurück zum Zitat Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z (1998) Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 8(2):107–114PubMedCrossRef Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z (1998) Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 8(2):107–114PubMedCrossRef
5.
Zurück zum Zitat Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF (2009) [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 115(15):3519–3525PubMedPubMedCentralCrossRef Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF (2009) [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 115(15):3519–3525PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47(3):551–560PubMedCrossRef Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47(3):551–560PubMedCrossRef
7.
Zurück zum Zitat Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL (1999) Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology. 213(2):530–536PubMedCrossRef Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL (1999) Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology. 213(2):530–536PubMedCrossRef
8.
Zurück zum Zitat Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. Jama. 285(7):914–924PubMedCrossRef Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. Jama. 285(7):914–924PubMedCrossRef
9.
Zurück zum Zitat Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR (2003) Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 125(4):938–944PubMedCrossRef Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR (2003) Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 125(4):938–944PubMedCrossRef
10.
Zurück zum Zitat Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, Ball DL, Peters LJ (2004) Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60(2):412–418PubMedCrossRef Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, Ball DL, Peters LJ (2004) Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60(2):412–418PubMedCrossRef
11.
Zurück zum Zitat Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21(7):1285–1292PubMedCrossRef Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21(7):1285–1292PubMedCrossRef
12.
Zurück zum Zitat Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507PubMedCrossRef Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507PubMedCrossRef
13.
Zurück zum Zitat van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (London, England) 359(9315):1388–1393CrossRef van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (London, England) 359(9315):1388–1393CrossRef
14.
Zurück zum Zitat Mac Manus MP, Wong K, Hicks RJ, Matthews JP, Wirth A, Ball DL (2002) Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 52(2):351–361PubMedCrossRef Mac Manus MP, Wong K, Hicks RJ, Matthews JP, Wirth A, Ball DL (2002) Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 52(2):351–361PubMedCrossRef
15.
Zurück zum Zitat Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A (2001) F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 92(4):886–895PubMedCrossRef Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A (2001) F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 92(4):886–895PubMedCrossRef
16.
Zurück zum Zitat Kepka L, Socha J (2015) PET-CT use and the occurrence of elective nodal failure in involved field radiotherapy for non-small cell lung cancer: a systematic review. Radiother Oncol 115(2):151–156PubMedCrossRef Kepka L, Socha J (2015) PET-CT use and the occurrence of elective nodal failure in involved field radiotherapy for non-small cell lung cancer: a systematic review. Radiother Oncol 115(2):151–156PubMedCrossRef
17.
Zurück zum Zitat Pu AT, Harrison AS, Robertson JM, Hayman JA, Martel MK et al (1997) The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 39(abst 2):196CrossRef Pu AT, Harrison AS, Robertson JM, Hayman JA, Martel MK et al (1997) The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 39(abst 2):196CrossRef
18.
Zurück zum Zitat Marks LB, Prosnitz LR (1999) Assessing the impact of elective regional radiotherapy on survival. Cancer J Sci Am 5(2):92–100PubMed Marks LB, Prosnitz LR (1999) Assessing the impact of elective regional radiotherapy on survival. Cancer J Sci Am 5(2):92–100PubMed
19.
Zurück zum Zitat Rosenzweig KE, Fox JL, Yorke E, Amols H, Jackson A, Rusch V, Kris MG, Ling CC, Leibel SA (2005) Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 103(10):2118–2127PubMedCrossRef Rosenzweig KE, Fox JL, Yorke E, Amols H, Jackson A, Rusch V, Kris MG, Ling CC, Leibel SA (2005) Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 103(10):2118–2127PubMedCrossRef
20.
Zurück zum Zitat Rosenzweig KE, Sura S, Jackson A, Yorke E (2007) Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 25(35):5557–5561PubMedCrossRef Rosenzweig KE, Sura S, Jackson A, Yorke E (2007) Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 25(35):5557–5561PubMedCrossRef
21.
Zurück zum Zitat Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J (2003) The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer (Amsterdam, Netherlands) 41(2):207–214CrossRef Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J (2003) The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer (Amsterdam, Netherlands) 41(2):207–214CrossRef
22.
Zurück zum Zitat Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1997) Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 38(3):521–525PubMedCrossRef Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1997) Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 38(3):521–525PubMedCrossRef
23.
Zurück zum Zitat MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, Danna M, Inoue T, Deniaud-Alexandre E, Schipani S, Watanabe N, Dondi M, Jeremic B (2009) Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 91(1):85–94PubMedCrossRef MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, Danna M, Inoue T, Deniaud-Alexandre E, Schipani S, Watanabe N, Dondi M, Jeremic B (2009) Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 91(1):85–94PubMedCrossRef
24.
Zurück zum Zitat Messa C, Di Muzio N, Picchio M, Gilardi MC, Bettinardi V, Fazio F (2006) PET/CT and radiotherapy. Q J Nucl Med Mol Imaging 50(1):4–14PubMed Messa C, Di Muzio N, Picchio M, Gilardi MC, Bettinardi V, Fazio F (2006) PET/CT and radiotherapy. Q J Nucl Med Mol Imaging 50(1):4–14PubMed
25.
Zurück zum Zitat Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, el Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN (2005) Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63(5):1432–1441PubMedCrossRef Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, el Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN (2005) Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63(5):1432–1441PubMedCrossRef
26.
Zurück zum Zitat Everitt S, Herschtal A, Callahan J, Plumridge N, Ball D, Kron T, Schneider-Kolsky M, Binns D, Hicks RJ, MacManus M (2010) High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer. 116(21):5030–5037PubMedCrossRef Everitt S, Herschtal A, Callahan J, Plumridge N, Ball D, Kron T, Schneider-Kolsky M, Binns D, Hicks RJ, MacManus M (2010) High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer. 116(21):5030–5037PubMedCrossRef
27.
Zurück zum Zitat De Ruysscher D, Nestle U, Jeraj R, Macmanus M (2012) PET scans in radiotherapy planning of lung cancer. Lung Cancer (Amsterdam, Netherlands). 75(2):141–145CrossRef De Ruysscher D, Nestle U, Jeraj R, Macmanus M (2012) PET scans in radiotherapy planning of lung cancer. Lung Cancer (Amsterdam, Netherlands). 75(2):141–145CrossRef
28.
Zurück zum Zitat Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schafers HJ (2003) Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 75(1):231–235 discussion 5-6PubMedCrossRef Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schafers HJ (2003) Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 75(1):231–235 discussion 5-6PubMedCrossRef
29.
Zurück zum Zitat Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM (2001) Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie (Stuttgart, Germany) 55(8):367–377CrossRef Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM (2001) Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie (Stuttgart, Germany) 55(8):367–377CrossRef
30.
Zurück zum Zitat Sattler B, Lee JA, Lonsdale M, Coche E (2010) PET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning. Radiother Oncol 96(3):288–297PubMedCrossRef Sattler B, Lee JA, Lonsdale M, Coche E (2010) PET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning. Radiother Oncol 96(3):288–297PubMedCrossRef
31.
Zurück zum Zitat Weber WA, Dietlein M, Hellwig D, Kirsch CM, Schicha H, Schwaiger M (2003) PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin 42(4):135–144PubMedCrossRef Weber WA, Dietlein M, Hellwig D, Kirsch CM, Schicha H, Schwaiger M (2003) PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin 42(4):135–144PubMedCrossRef
32.
Zurück zum Zitat Grgic A, Nestle U, Schaefer-Schuler A, Kremp S, Kirsch CM, Hellwig D (2009) FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning--an intraindividual comparison. Int J Radiat Oncol Biol Phys 73(1):103–111PubMedCrossRef Grgic A, Nestle U, Schaefer-Schuler A, Kremp S, Kirsch CM, Hellwig D (2009) FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning--an intraindividual comparison. Int J Radiat Oncol Biol Phys 73(1):103–111PubMedCrossRef
33.
Zurück zum Zitat Nehmeh SA, Erdi YE, Rosenzweig KE, Schoder H, Larson SM, Squire OD et al (2003) Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. J Nucl Med 44(10):1644–1648PubMed Nehmeh SA, Erdi YE, Rosenzweig KE, Schoder H, Larson SM, Squire OD et al (2003) Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. J Nucl Med 44(10):1644–1648PubMed
34.
Zurück zum Zitat Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C et al (2005) Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46(8):1342–1348PubMed Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C et al (2005) Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46(8):1342–1348PubMed
Metadaten
Titel
ICORG 06-35: a prospective evaluation of PET-CT scan in patients with non-operable or non-resectable non-small cell lung cancer treated by radical 3-dimensional conformal radiation therapy: a phase II study
verfasst von
Karla A. Lee
Guhan Rangaswamy
Naomi A. Lavan
Mary Dunne
Conor D. Collins
Cormac Small
Pierre Thirion
Publikationsdatum
06.05.2019
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 4/2019
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-019-02019-2

Weitere Artikel der Ausgabe 4/2019

Irish Journal of Medical Science (1971 -) 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.